Novel Treatment and Management Options for Chronic Idiopathic Constipation

Complimentary

Released on July 23, 2021
Expires on July 23, 2022

Categories: , , , , , , , , , ,
Person clutching stomach in pain with red highlight on abdomen.

Start Activity

Program Description

The activity is designed to provide the latest data in diagnosis and give real-world examples and recommendations for chronic idiopathic constipation (CIC) treatment. Dietary and lifestyle adjustments should be attempted first before initiating pharmacological treatments for CIC. Pharmacological management should be considered if lifestyle and dietary measures do not provide adequate relief of CIC. First-line pharmacological treatments recommended in primary care include bulking agents, osmotic laxatives, and stool softeners. Combination therapy with agents across different classes/mechanisms can be considered before moving to second-line treatment. Patients not responding to traditional laxatives should be offered treatment with secretagogues such as lubiprostone, linaclotide, plecanatide, or the 5-HT4 receptor agonist prucalopride. If there is no response to pharmacological treatment, surgical intervention can be considered, but it is only suitable for a carefully selected subset of patients with proven slow transit constipation. This educational activity will familiarize the need for early diagnosis and treatment, new data to optimize the use of novel agents currently available.

Intended Audience

This webcast is designed to meet the educational needs of gastroenterologists, primary care physicians, physician assistants, nurse practitioners, and nurses involved in the diagnosis and treatment of chronic idiopathic constipation (CIC).

Commercial Supporter

Supported by AbbVie, Inc.

Educational Objectives

  • Evaluate the guideline recommendations to diagnose patients with CIC and set appropriate treatment goals
  • Assess the efficacy and safety of novel therapies in the management of relief for patients with CIC
  • Appraise the strategies for a multidisciplinary approach and care coordination to achieve treatment goals and improve patient outcomes

Accredited Providers

Jointly provided by Amedco, a CME/CE company, and MedNet


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Designation Statement

Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Designation Statement

Amedco LLC designates this enduring material activity for a maximum of 1.50 ANCC contact hours.

Additional Credit Information

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours.

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Kamatham A. Naidu, PhD (CancerNet) has no relevant financial relationships to disclose.
Brian Waggoner (MedNet, LLC) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Conflicts of Interest Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Faculty

Anthony Lembo, MD
Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, MA

Dr. Lembo discloses that he is on the advisory board of Mylan Pharmaceuticals, Ironwood Pharmaceuticals, Vibrant, Takeda Pharmaceuticals, Aeon, Bayer, Shire, Arena, Orphomed, and Bellatrix.

Satish SC Rao, MD, PhD
Professor of Medicine,
Medical College of Georgia
Augusta, GA

Dr. Rao discloses he is on the advisory board of Mylan Pharmaceuticals, Salix Pharmaceuticals, Ironwood Pharmaceuticals, Vibrant, Takeda Pharmaceuticals; and received research support from National Institutes of Health, NIDDK, and Vibrant.

Instructions

There are no fees for participating and receiving CME/CE credit for this webcast. During the period July 23, 2021 through July 23, 2022, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 75% or better on the post-assessment is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

Webcast

Time to Complete: 90 minutes

Released: July 23, 2021

Expires: July 23, 2022

Maximum Credits:
1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / ANCC Contact Hour(s)

Related products